四环医药2024年度报告

(incorporated in Bermuda with limited liability)（於百慕達註冊成立之有限公司）StockCode股份代號：0460 公司簡介CORPORATE PROFILE 四環醫藥控股集團有限公司（「」或「」，連同其附屬公司為「」）（股份代號：00460.HK）創立於二零零一年，二零一零年於香港聯合交易所有限公司主板上市，是一家以創新為引領，堅持創新驅動，擁有獨立領先的自主生產、研究與開發（「」）技術平台，具備豐富的全球化產品管線和成熟卓越銷售體系的國際化醫美及生物製藥企業。四環醫藥聚焦醫 美、腫 瘤、代 謝、糖 尿 病、心 腦 血 管、現 代中藥及工業大麻等高增長治療領域，一直秉承「堅持全速推進四環醫美及生物製藥雙輪驅動戰略」的整體戰略目標來打造中國領先的醫美及生物製藥企業。 Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong KongLimited in 2010, Sihuan Pharmaceutical Holdings Group Ltd. (“Sihuan Pharmaceutical”or the “Company”, together with its subsidiaries, the “Group”) (Stock Code:00460.HK) is an international medical aesthetic and biopharmaceutical companyled and driven by innovation, with a leading independent production, and researchand development (“R&D”) technology platform, a rich global product pipeline and amature and excellent sales system. Focusing on high-growth therapeutic areas such asmedical aesthetics, oncology, metabolism, diabetes, cardiovascular and cerebrovascular,modern Chinese medicine and industrial hemp, it adheres to its overall strategicobjective of “Adhering to the full-speed promotion of a two-wheeled strategy of Sihuanmedical aesthetics and biopharmaceuticals” to build a leading medical aesthetics andbiopharmaceutical enterprise in China. 目錄CONTENTS 115獨立核數師報告Independent Auditor’s Report122綜合損益及其他全面收益表Consolidated Statement of Profit or Loss andOther Comprehensive Income124綜合財務狀況表Consolidated Statement of Financial Position126綜合權益變動表Consolidated Statement of Changes in Equity128綜合現金流量表Consolidated Statement of Cash Flows130財務報表附註Notes to the Financial Statements280物業詳情Particulars of Properties 2公司資料Corporate Information4發展里程Milestones16獎項Awards21財務摘要Financial Summary22主席報告Chairman’s Statement26管理層討論及分析Management Discussion and Analysis57董事履歷Biographical Details of Directors62企業管治報告Corporate Governance Report88董事會報告Report of Directors 公司資料CORPORATE INFORMATION BOARD OF DIRECTORS (THE “BOARD”) Executive Directors 車馮升醫生（主席）郭維城醫生（副主席兼行政總裁）張炯龍醫生繆瑰麗女士（副行政總裁兼首席財務官）陳燕玲女士 Dr. Che Fengsheng (Chairman)Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer (“CEO”))Dr. Zhang JionglongMs. Miao Guili (Deputy CEO and Chief Financial Officer (“CFO”))Ms. Chen Yanling 曾華光先生朱迅博士王冠先生 Independent Non-executive Directors Mr. Tsang Wah KwongDr. Zhu XunMr. Wang Guan JOINT COMPANY SECRETARIES 陳燕玲女士李健威先生 Ms. Chen YanlingMr. Li Kin Wai AUTHORISED REPRESENTATIVES 陳燕玲女士李健威先生 Ms. Chen YanlingMr. Li Kin Wai AUDIT COMMITTEE 曾華光先生（主席）朱迅博士王冠先生 Mr. Tsang Wah Kwong (Chairman)Dr. Zhu XunMr. Wang Guan REMUNERATION COMMITTEE 朱迅博士（主席）車馮升醫生曾華光先生王冠先生 Dr. Zhu Xun (Chairman)Dr. Che FengshengMr. Tsang Wah KwongMr. Wang Guan NOMINATION COMMITTEE 王冠先生（主席）郭維城醫生曾華光先生朱迅博士 Mr. Wang Guan (Chairman)Dr. Guo WeichengMr. Tsang Wah KwongDr. Zhu Xun RISK MANAGEMENT COMMITTEE 陳燕玲女士（聯席主席）繆瑰麗女士（聯席主席）郭維城醫生曾華光先生 Ms. Chen Yanling (Co-chairman)Ms. Miao Guili (Co-chairman)Dr. Guo WeichengMr. Tsang Wah Kwong INDEPENDENT AUDITOR 安永會計師事務所執業會計師及註冊公眾利益實體核數師香港鰂魚涌英皇道979號太古坊一座27樓 Ernst & YoungCertified Public Accountants and Registered Public Interest Entity Auditor27/F, One Taikoo Place979 King’s RoadQuarry Bay, Hong Kong REGISTERED OFFICE Clarendon House2 Church StreetHamilton HM 11Bermuda Clarendon House2 Church StreetHamilton HM 11Bermuda PRINCIPAL PLACE OF BUSINESS IN HONG KONG 香港灣仔港灣道1號會展廣場辦公大樓4905室 Room 4905, Office Tower, Convention Plaza1 Harbour RoadWanchai, Hong Kong PRINCIPAL SHARE REGISTRAR Conyers Corporate Services (Bermuda) LimitedClarendon House2 Church StreetHamilton HM 11Bermuda Conyers Corporate Services (Bermuda) LimitedClarendon House2 Church StreetHamilton HM 11Bermuda HONG KONG BRANCH SHARE REGISTRAR 卓佳證券登記有限公司香港夏愨道16號遠東金融中心17樓 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt Road, Hong Kong WEBSITE www.sihuanpharm.com www.sihuanpharm.com STOCK CODE 0460 0460 發展里程MILESTONES 2024 •二 零 二 四 年 十 二 月，北 京 銳 業 製 藥 有 限公司（「」）研發的注射用頭孢哌酮 舒 巴 坦 ╱ 氯 化 鈉 注 射 液、惠 升 生 物 製藥 股 份 有 限 公 司（「」）研 發 的SGLT-2抑制劑創新藥脯氨酸加格列淨片新 增 納 入《國 家 基 本 醫 療 保 險、工 傷 保險和生育保險藥品目錄（2024年）》（簡稱「2024」），此 次 被 納入國家醫保目錄（2024年），將加速產品的 市 場 滲 透，有 利 於 產 品 商 業 化，對 本公 司 業 績 產 生 積 極 影 響。另 外，加 格 列淨於年內成功進入《中國糖尿病防治指南（2024版）》，進 一 步 明 確 了 加 格 列 淨 在糖 尿 病 治 療 中 的 地 位 和 作 用，有 助 於 提升銷量和市場佔有率。 •In December 2024, Cefoperazone Sodium and Sulbactam Sodium for Injection/Sodium Chloride Injection developed by Beijing Ruiye Pharmaceutical Co., Ltd.(“Beijing Ruiye”), and SGLT-2 inhibitor innovative drug Proline Ganagliflozintablets developed by Huisheng Biopharmaceutical Co., Ltd. (“HuishengBiopharm”), had been newly added into the National Basic Medical Insurance,Work-related Injury Insurance and Maternity Insurance (2024) (《國 家 基 本 醫 療保險、工傷保險和生育保險藥品目錄(2024年)》) (“National ReimbursementDrug List (2024)”). The inclusion in the National Reimbursement Drug List(2024) is expected to accelerate market penetration of these products, facilitatetheir commercialisation, and have a positive impact on the Company’s fin